Bank of Montreal Can Grows Stake in argenx SE (NASDAQ:ARGX)

Bank of Montreal Can grew its position in argenx SE (NASDAQ:ARGX) by 11.2% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 9,236 shares of the company’s stock after buying an additional 929 shares during the quarter. Bank of Montreal Can’s holdings in argenx were worth $5,680,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. Whipplewood Advisors LLC purchased a new stake in argenx in the fourth quarter worth about $37,000. Global Retirement Partners LLC lifted its position in shares of argenx by 369.2% in the 4th quarter. Global Retirement Partners LLC now owns 61 shares of the company’s stock worth $38,000 after purchasing an additional 48 shares during the period. Jones Financial Companies Lllp boosted its stake in shares of argenx by 1,016.7% during the fourth quarter. Jones Financial Companies Lllp now owns 67 shares of the company’s stock valued at $41,000 after purchasing an additional 61 shares in the last quarter. Huntington National Bank increased its holdings in argenx by 1,133.3% during the fourth quarter. Huntington National Bank now owns 74 shares of the company’s stock valued at $46,000 after buying an additional 68 shares during the period. Finally, Whittier Trust Co. of Nevada Inc. raised its stake in argenx by 78.6% in the fourth quarter. Whittier Trust Co. of Nevada Inc. now owns 75 shares of the company’s stock worth $46,000 after buying an additional 33 shares in the last quarter. Institutional investors own 60.32% of the company’s stock.

argenx Trading Up 4.4 %

Shares of NASDAQ ARGX opened at $606.39 on Tuesday. The company has a 50 day simple moving average of $606.57 and a two-hundred day simple moving average of $604.95. The stock has a market cap of $36.84 billion, a price-to-earnings ratio of -689.08 and a beta of 0.60. argenx SE has a 12 month low of $352.77 and a 12 month high of $678.21.

argenx (NASDAQ:ARGX) last posted its quarterly earnings results on Thursday, February 27th. The company reported $1.58 EPS for the quarter, beating the consensus estimate of $0.98 by $0.60. The company had revenue of $761.22 million for the quarter, compared to analyst estimates of $678.52 million. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. Analysts forecast that argenx SE will post 3.13 EPS for the current year.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on ARGX shares. Wedbush reissued an “outperform” rating and issued a $715.00 price target on shares of argenx in a research report on Friday. Oppenheimer raised their price target on shares of argenx from $675.00 to $704.00 and gave the company an “outperform” rating in a report on Friday, February 28th. Robert W. Baird boosted their price objective on shares of argenx from $650.00 to $680.00 and gave the stock a “neutral” rating in a research note on Tuesday, March 4th. William Blair restated an “outperform” rating on shares of argenx in a research note on Friday, February 28th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $720.00 price target on shares of argenx in a research report on Tuesday, April 8th. Three research analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $690.33.

argenx Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.